Formulation and Characterization of Fast-Dissolving Sublingual Film of Iloperidone Using Box–Behnken Design for Enhancement of Oral Bioavailability
Iloperidone is a second-generation antipsychotic drug which is used for the treatment of schizophrenia and has very low aqueous solubility and bioavailability. This drug also undergoes first-pass metabolism. The aim of this work is to formulate fast-dissolving sublingual films of iloperidone to improve its bioavailability. Sublingual films were prepared by solvent casting method. Hydroxypropyl methyl cellulose E5, propylene glycol 400, and transcutol HP were optimized using Box–Behnken three-level statistical design on the basis of disintegration time and folding endurance of films. Iloperidone:hydroxypropyl-β–cyclodextrin kneaded complex was used in films instead of plain drug due to its low solubility. Optimized film was further evaluated for drug content, pH, dissolution studies, ex vivo permeation studies, and pharmacokinetic studies in rats. The optimized film disintegrated within 30 s. The in vitro dissolution of the film showed 80.3 ± 3.4% drug dissolved within first 5 min. In ex vivo permeation studies using sublingual tissue, flux achieved within first 15 min by film was around 117.1 ± 0.35 (mcg/cm2/h) which was ten times more than that of plain drug. This formulation showed excellent uniformity. AUC and Cmax of film were significantly higher (p < 0.001) as compared to plain drug and relative bioavailability of the films was 148% when compared to the plain drug. Thus, this study showed optimized fast-dissolving sublingual film to improve permeation and bioavailability of iloperidone. Fast-dissolving films will be customer-friendly approach for geadiatric schizophrenic patients.
KEY WORDSiloperidone sublingual film Box–Behnken statistical design ex vivo permeation study pharmacokinetic studies
Authors would like to thank Lupin Ltd. for providing iloperidone gift sample and Gattefosse for providing transcutol HP gift sample. We would like to also thank Mr. Ankit Laddha, research scholar, SPPSPTM for helping in pharmacokinetic studies.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.Jhanjee A, Bhatia MS, Rathi A. Iloperidone–a Novel Drug for treatment of schizophrenia. Delhi Psychiatry J. 2012;5(1):204–7.Google Scholar
- 9.Mandpe L, Pokharkar V. Targeted brain delivery of iloperidone nanostructured lipid carriers following intranasal administration: in vivo pharmacokinetics and brain distribution studies. J Nanopharmaceutics and Drug Delivery. 2013;1(2):212–25. https://doi.org/10.1166/jnd.2013.1019.CrossRefGoogle Scholar
- 10.Siddiqui MN, Garg G, Sharma PK. A short review on-a novel approach in oral fast dissolving drug delivery system and their patents. Adv Biol Res. 2011;5(6):291–303.Google Scholar
- 11.Mansi M. Formulation and evaluation of fast dissolving film of lurasidone. Int J Pharm Res Bio. 2016;5(2):101–23.Google Scholar
- 12.Bhowmik D, Chiranjib B, Krishnakanth P, Chandira RM. Fast dissolving tablet: an overview. J Chem Pharm Res. 2009;1(1):163–77.Google Scholar
- 13.Puttalingaiah L, Mani T. Fast disintegrating tablets: an overview of formulation, technology and evaluation. Res J Pharm Biol Chem Sci. 2011;2(2):589–601.Google Scholar
- 14.Malviya R, Sharma PK. Trends in buccal film: formulation characteristics, recent studies and patents. Eur J Appl Sci. 2011;3(3):93–101.Google Scholar
- 16.Zidan AS, Sammour OA, Hammad MA, Megrab NA, Habib MJ, Khan MA. Quality by design: understanding the formulate on variables of a cyclosporine A self-nanoemulsified drug delivery systems by Box-Behnken design and desirability function. Int J Pharm. 2007;332(1–2):55–63. https://doi.org/10.1016/j.ijpharm.2006.09.060.CrossRefPubMedGoogle Scholar
- 17.Elbary AA, Aboelwafa AA, Sharabi IM. Once daily, high-dose mesalazine controlled-release tablet for colonic delivery: optimization of formulation variables using Box-Behnken design. AAPS PharmSciTech. 2011;12(4):1454–64. https://doi.org/10.1208/s12249-011-9708-9.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Basalious EB, El-Sebaie W, El-Gazayerly O. Application of pharmaceutical QbD for enhancement of the solubility and dissolution of a class II BCS drug using polymeric surfactants and crystallization inhibitors: development of controlled-release tablets. AAPS PharmSciTech. 2011;12(3):799–810.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Patil P, Shrivastava SK. Fast dissolving oral films: an innovative drug delivery system. Int J Sci Res. 2014;3(7):2088–92.Google Scholar
- 30.Tomar A, Sharma K, Chauhan NS, et al. Formulation and evaluation of fast dissolving oral film of dicyclomine as potential route of buccal delivery. Int J Drug Dev Res. 2012;4(2):408–17.Google Scholar
- 32.Wu L, Qiao Y, Wang L, Guo J, Wang G, He W, et al. A self-microemulsifying drug delivery system (SMEDDS) for a novel medicative compound against depression: a preparation and bioavailability study in rats. AAPS PharmSciTech. 2015;16(5):1051–8. https://doi.org/10.1208/s12249-014-0280-y.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Mura P, Faucci MT, Bramanti G, Corti P. Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations. Eur J Pharm Biopharm. 2000;9(4):365–72.Google Scholar
- 36.Rathi AA, Dhamecha DL, Patel KA, et al. Effect of permeation enhancers on permeation kinetics of idebenone through the bovine buccal mucosa. Ind J Pharm Edu Res. 2011;45(4):370–4.Google Scholar